Neuphoria Therapeutics, Inc. - NEUP Earnings per share for the trailing year

The lack of current monetization leaves Neuphoria Therapeutics Inc. (NEUP) dependent on external financing and grants. High R&D costs are offset by the prospect of licensing formulas to industry behemoths. Meanwhile, creating a CNS blockbuster would ensure global reach with minimal substance synthesis. The annual shift in EPS TTM reflects profit dynamics, where 78.30 is the current value of the indicator.
Neuphoria Therapeutics Inc. - analytical breakdowns and key metrics (NEUP)

Year-over-year (TTM) EPS growth measures the percentage change in net income per share over the last twelve months, allowing investors to assess the scaling rate of the business's actual income. By analyzing the year-over-year (TTM) EPS dynamics, one can determine how successfully Neuphoria Therapeutics Inc. (NEUP) is monetizing its innovations in the field of psychiatric disorder therapy and neurology.